Synonym:BMS354825;BMS-354825;BMS354825.Dasatinib;USbrandname:Sprycel.

IUPAC/ChemicalName:N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamidemonohydrate.

InChiKey:XHXFZZNHDVTMLI-UHFFFAOYSA-N

InChiCode:InChI=1S/C22H26ClN7O2S.H2O/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31;/h4-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27);1H2

SMILESCode:O=C(C1=CN=C(NC2=NC(C)=NC(N3CCN(CCO)CC3)=C2)S1)NC4=C(C)C=CC=C4Cl.[H]O[H]

TechnicalData

AdditionalInformation

RelatedCAS#
863127-77-9(Dasatinibmonohydrate);
302962-49-8(Dasatinib).

References

1:KorashyHM,RahmanAF,KassemMG.Dasatinib.ProfilesDrugSubstExcipRelatMethodol.2014;39:205-37.doi:10.1016/B978-0-12-800173-8.00004-0.Review.PubMedPMID:24794907.

2:LindauerM,HochhausA.Dasatinib.RecentResultsCancerRes.2014;201:27-65.doi:10.1007/978-3-642-54490-3_2.Review.PubMedPMID:24756784.

3:QiuZY,XuW,LiJY.Largegranularlymphocytosisduringdasatinibtherapy.CancerBiolTher.2014Mar1;15(3):247-55.doi:10.4161/cbt.27310.Epub2013Dec18.Review.PubMedPMID:24352048;PubMedCentralPMCID:PMC3974824.

4:NagaoT,TakahashiN,KameokaY,NoguchiS,ShinoharaY,OhyagiH,KumeM,SawadaK.Dasatinib-responsivechroniclymphocyticleukemiainapatienttreatedforcoexistingchronicmyeloidleukemia.InternMed.2013;52(22):2567-71.Review.PubMedPMID:24240798.

5:PaydasS.Dasatinib,largegranularlymphocytosis,andpleuraleffusion:usefuloradverseeffect?CritRevOncolHematol.2014Feb;89(2):242-7.doi:10.1016/j.critrevonc.2013.10.005.Epub2013Oct12.Review.PubMedPMID:24210599.

6:SignorovitchJ,AyyagariR,ReichmannWM,WuEQ,ChenL.Majormolecularresponseduringthefirstyearofdasatinib,imatinibornilotinibtreatmentfornewlydiagnosedchronicmyeloidleukemia:anetworkmeta-analysis.CancerTreatRev.2014Mar;40(2):285-92.doi:10.1016/j.ctrv.2013.09.004.Epub2013Sep17.Review.PubMedPMID:24112812.

7:EADIeLN,HughesTP,WhiteDL.InteractionoftheeffluxtransportersABCB1andABCG2withimatinib,nilotinib,anddasatinib.ClinPharmacolTher.2014Mar;95(3):294-306.doi:10.1038/clpt.2013.208.Epub2013Oct9.Review.PubMedPMID:24107928.

8:HochhausA,KantarjianH.Thedevelopmentofdasatinibasatreatmentforchronicmyeloidleukemia(CML):frominitialstudiestoapplicationinnewlydiagnosedpatients.JCancerResClinOncol.2013Dec;139(12):1971-84.doi:10.1007/s00432-013-1488-z.Epub2013Aug13.Review.PubMedPMID:23942795;PubMedCentralPMCID:PMC3825579.

9:BrazzelliV,GrassoV,BorroniG.Imatinib,dasatinibandnilotinib:areviewofadversecutaneousreactionswithemphasisonourclinicalexperience.JEurAcadDermatolVenereol.2013Dec;27(12):1471-80.doi:10.1111/jdv.12172.Epub2013Apr24.Review.PubMedPMID:23611501.

10:KeatingGM,Lyseng-WilliamsonKA,McCormackPL,KeamSJ.Dasatinib:aguidetoitsuseinchronicmyeloidleukemiaintheEU.BioDrugs.2013Jun;27(3):275-9.doi:10.1007/s40259-013-0024-7.Review.PubMedPMID:23549840.